A Phase 4 Randomized Trial Comparing Varithena to Endothermal Ablation for the Treatment of the Great Saphenous Vein
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs Polidocanol (Primary)
- Indications Varicose veins
- Focus Therapeutic Use
- Acronyms VERITAS
- Sponsors Boston Scientific Corporation
- 29 May 2024 Status changed from active, no longer recruiting to discontinued because of the challenges in enrolling patients and difficult insurance coverage landscape.
- 24 Apr 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Apr 2024.
- 24 Apr 2024 Status changed from recruiting to active, no longer recruiting.